Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma

Molecular Cancer

Alessandra Quarta¹  Gabriella Guida²  Roberta Di Fonte³  Rosa Maria Iacobazzi³  Letizia Porcelli³  Amalia Azzariti⁴  Simona Serratì⁴  Simona De Summa⁵  Sabino Strippoli⁶  Ivana De Risi⁶  Michele Guida⁶  Angelo Paradiso⁷ 

[1] CNR NANOTEC-Istituto di Nanotecnologia, National Research Council (CNR);Department of Basic Medical Sciences Neurosciences and Sense Organs, University of Bari;Laboratory of Experimental Pharmacology, IRCCS Istituto Tumori Giovanni Paolo II;Laboratory of Nanotechnology, IRCCS Istituto Tumori Giovanni Paolo II;Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori Giovanni Paolo II;Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori Giovanni Paolo II;Scientific Directorate, IRCCS Istituto Tumori Giovanni Paolo II;

关键词: Metastatic melanoma;    Drug resistance;    Extracellular vesicles;    PD1;    PD-L1;    Anti-PD1 treatment;   

DOI  :  10.1186/s12943-021-01490-9

来源: DOAJ

【 摘 要 】

Abstract Background The immunotherapy with immune checkpoints inhibitors (ICI) has changed the life expectancy in metastatic melanoma (MM) patients. Nevertheless, several patients do not respond hence, the identification and validation of novel biomarkers of response to ICI is of crucial importance. Circulating extracellular vesicles (EVs) such as PD-L1+ EV mediate resistance to anti-PD1, instead the role of PD1+ EV is not fully understood. Methods We isolated the circulating EVs from the plasma of an observational cohort study of 71 metastatic melanoma patients and correlated the amount of PD-L1+ EVs and PD1+ EVs with the response to ICI. The analysis was performed according to the origin of EVs from the tumor and the immune cells. Subsequently, we analysed the data in a validation cohort of 22 MM patients to assess the reliability of identified EV-based biomarkers. Additionally we assessed the involvement of PD1+ EVs in the seizure of nivolumab and in the perturbation of immune cells-mediated killing of melanoma spheroids. Results The level of PD-L1+ EVs released from melanoma and CD8+ T cells and that of PD1+ EVs irrespective of the cellular origin were higher in non-responders. The Kaplan-Meier curves indicated that higher levels of PD1+ EVs were significantly correlated with poorer progression-free survival (PFS) and overall survival (OS). Significant correlations were found for PD-L1+ EVs only when released from melanoma and T cells. The multivariate analysis showed that high level of PD1+ EVs, from T cells and B cells, and high level of PD-L1+ EVs from melanoma cells, are independent biomarkers of response. The reliability of PD-L1+ EVs from melanoma and PD1+ EVs from T cells in predicting PFS was confirmed in the validation cohort through the univariate Cox-hazard regression analysis. Moreover we discovered that the circulating EVs captured nivolumab and reduced the T cells trafficking and tumor spheroids killing. Conclusion Our study identified circulating PD1+ EVs as driver of resistance to anti-PD1, and highlighted that the analysis of single EV population by liquid biopsy is a promising tool to stratify MM patients for immunotherapy.

【 授权许可】

Unknown